Formation 1984 Official language English | Headquarters Milwaukee, WI Executive Director Tara Withington | |
Type Non-Profit Medical Society President Lisa H. Butterfield, PhD
University of Pittsburgh | ||
The Society for Immunotherapy of Cancer (SITC), previously known as The International Society for Biological Therapy of Cancer (iSBTc)[1] is a professional society of influential scientists, academicians, researchers, clinicians, government representatives, and industry leaders from around the world dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy. Currently, SITC has nearly 1,700 members, representing 17 medical specialties, who are engaged in the research and treatment of at least a dozen types of cancer.
Contents
Through emphasis on high-caliber scientific meetings, dedication to education and outreach activities, focus on initiatives of major importance to the field, and commitment to collaborations with like-minded organizations and patient advocacy groups, SITC brings together all aspects of the cancer immunology and immunotherapy community in an effort to make cancer immunotherapy one of the four standards of care and the word “cure” a reality for cancer patients living with this disease.
The goals of SITC are directed towards the rapid dissemination of information in these areas to expedite the safe transfer of both basic and applied research to the clinical setting.
Core Values
Interaction/Integration - Facilitate the exchange of information and education among basic and translational researchers, practitioners, young investigators, societies and groups sharing the mission of SITC
Innovation - Challenge the thinking and seek the best research in the development of cancer immunotherapy
Translation - Facilitate the transfer of cancer immunology and immunotherapy research from the bench to the clinic and back
Leadership - Define what is new and important and effectively communicate it to all relevant stakeholders
Activities
SITC continues to increase the number of programs it offers [2] each year. The purpose of these programs – which include the Annual Meeting & Pre-Conference Programs, Advances in Cancer Immunotherapy™ educational series, and an array of collaborative education programs – is to bring together leaders to discuss the latest developments in cancer immunotherapy and biological therapy, and to focus on and educate the clinical and translational aspects of biologic approaches to cancer treatment.
Membership
SITC's membership consists leaders in the field of cancer immunotherapy and up-and-coming scientists. This group includes academicians, government representatives, industry leaders, senior investigators and students. SITC’s members represent 17 medical specialties and are engaged in research and treatment of at least a dozen types of cancer.
Publications
The Journal for ImmunoTherapy of Cancer (JITC) is the official journal of the Society for Immunotherapy of Cancer (SITC). It is an open access, online journal created by the Society for the many stakeholders in the tumor immunology and cancer immunotherapy community. JITC is an outlet and targeted publication platform dedicated to advancing the science of tumor immunology and cancer immunotherapy.